脂質低下薬剤のグローバル市場予測2023-2029

◆英語タイトル:Global Lipid-lowering Drugs Market Growth 2023-2029

LP Informationが発行した調査報告書(LP23OT9059)◆商品コード:LP23OT9059
◆発行会社(リサーチ会社):LP Information
◆発行日:2023年10月
◆ページ数:101
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後2-3営業日)
◆調査対象地域:グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など
◆産業分野:医薬品&ヘルスケア
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,660 ⇒換算¥549,000見積依頼/購入/質問フォーム
Multi User(20名様閲覧用)USD5,490 ⇒換算¥823,500見積依頼/購入/質問フォーム
Corporate User(閲覧人数制限なし)USD7,320 ⇒換算¥1,098,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

LP Informationの最新刊調査レポート「脂質低下薬剤のグローバル市場」は、過去の販売実績から2022年の世界の脂質低下薬剤の総販売量を検討し、2023年から2029年の予測される脂質低下薬剤の販売量を地域別・市場分野別に包括的に分析しています。本調査レポートでは、地域別、市場分野別、サブセクター別の脂質低下薬剤の市場規模を掲載し、XXX百万米ドル規模の世界の脂質低下薬剤市場の詳細な分析を提供します。本インサイトレポートは、世界の脂質低下薬剤業界を包括的に分析し、製品セグメント、企業情報、売上、市場シェア、最新動向、M&A活動に関する主要トレンドを明らかにしています。
また、本レポートでは、加速する世界の脂質低下薬剤市場における各社の独自のポジションをより深く理解するために、脂質低下薬剤製品ポートフォリオ、能力、市場参入戦略、市場でのポジション、海外展開に焦点を当て、主要なグローバル企業の戦略を分析しています。

世界の脂質低下薬剤市場規模は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに成長すると予測され、2023年から2029年までの年平均成長率は000%と予測されます。脂質低下薬剤の米国市場は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加し、2023年から2029年までのCAGRは000%と予測されています。脂質低下薬剤の中国市場は、2023年から2029年までの年平均000%成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されます。脂質低下薬剤のヨーロッパ市場は、2023年から2029年にかけて年平均000%成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されています。

脂質低下薬剤の世界主要メーカーとしては、Sanofi、 Pfizer, Inc.、 GlaxoSmithKline plc、 Novartis AG、 Merck & Co., Inc.、 Amgen Inc.、 Takeda Pharmaceutical Company Limited、 Sun Pharmaceutical Industries Ltd.、 AbbVie, Inc.、 Viatris (Mylan N.V.)、 AstraZeneca PLC、 Dr. Reddy’s Laboratories Ltd.などを掲載しており、売上の面では、世界の2大企業が2022年にほぼ000%のシェアを占めています。

本レポートでは、製品タイプ、用途、主要メーカー、主要地域、国別の脂質低下薬剤市場の包括的な概要、市場シェア、成長機会などの情報を提供しています。

【市場セグメンテーション】

この調査では脂質低下薬剤市場をセグメンテーションし、種類別 (スタチン&配合剤、PCSK9阻害剤、胆汁酸封鎖剤、フィブラート系薬剤、コレステロール吸収阻害剤、その他)、用途別 (病院薬局、小売薬局、オンライン薬局)、および地域別 (アジア太平洋、南北アメリカ、ヨーロッパ、および中東・アフリカ) の市場規模を予測しています。

・種類別区分:スタチン&配合剤、PCSK9阻害剤、胆汁酸封鎖剤、フィブラート系薬剤、コレステロール吸収阻害剤、その他

・用途別区分:病院薬局、小売薬局、オンライン薬局

・地域別区分
南北アメリカ(米国、カナダ、メキシコ、ブラジル)
アジア太平洋(中国、日本、韓国、東南アジア、インド、オーストラリア)
ヨーロッパ(ドイツ、フランス、イギリス、イタリア、ロシア)
中東・アフリカ(エジプト、南アフリカ、イスラエル、トルコ、GCC諸国)

【本レポートで扱う主な質問】

・世界の脂質低下薬剤市場の10年間の市場状況・展望は?
・世界および地域別に見た脂質低下薬剤市場成長の要因は何か?
・脂質低下薬剤の市場機会はエンドマーケットの規模によってどのように変化するのか?
・脂質低下薬剤のタイプ別、用途別の内訳は?
・新型コロナウイルスとロシア・ウクライナ戦争の影響は?

********* 目次 *********

レポートの範囲
・市場の紹介
・分析対象期間
・調査の目的
・調査手法
・調査プロセスおよびデータソース
・経済指標
・通貨

エグゼクティブサマリー
・世界市場の概要:脂質低下薬剤の年間販売量2018-2029、地域別現状・将来分析
・脂質低下薬剤の種類別セグメント:スタチン&配合剤、PCSK9阻害剤、胆汁酸封鎖剤、フィブラート系薬剤、コレステロール吸収阻害剤、その他
・脂質低下薬剤の種類別販売量:2018-2023年の販売量、売上、市場シェア、販売価格
・脂質低下薬剤の用途別セグメント:病院薬局、小売薬局、オンライン薬局
・脂質低下薬剤の用途別販売量:2018-2023年の販売量、売上、市場シェア、販売価格

企業別世界の脂質低下薬剤市場
・企業別のグローバル脂質低下薬剤市場データ:2018-2023年の年間販売量、市場シェア
・企業別の脂質低下薬剤の年間売上:2018-2023年の売上、市場シェア
・企業別の脂質低下薬剤販売価格
・主要企業の脂質低下薬剤生産地域、販売地域、製品タイプ
・市場集中度分析
・新製品および潜在的な参加者
・合併と買収、拡大

脂質低下薬剤の地域別レビュー
・地域別の脂質低下薬剤市場規模2018-2023:年間販売量、売上
・主要国別の脂質低下薬剤市場規模2018-2023:年間販売量、売上
・南北アメリカの脂質低下薬剤販売の成長
・アジア太平洋の脂質低下薬剤販売の成長
・ヨーロッパの脂質低下薬剤販売の成長
・中東・アフリカの脂質低下薬剤販売の成長

南北アメリカ市場
・南北アメリカの国別の脂質低下薬剤販売量、売上(2018-2023)
・南北アメリカの脂質低下薬剤の種類別販売量
・南北アメリカの脂質低下薬剤の用途別販売量
・米国市場
・カナダ市場
・メキシコ市場
・ブラジル市場

アジア太平洋市場
・アジア太平洋の国別の脂質低下薬剤販売量、売上(2018-2023)
・アジア太平洋の脂質低下薬剤の種類別販売量
・アジア太平洋の脂質低下薬剤の用途別販売量
・中国市場
・日本市場
・韓国市場
・東南アジア市場
・インド市場
・オーストラリア市場
・台湾市場

ヨーロッパ市場
・ヨーロッパの国別の脂質低下薬剤販売量、売上(2018-2023)
・ヨーロッパの脂質低下薬剤の種類別販売量
・ヨーロッパの脂質低下薬剤の用途別販売量
・ドイツ市場
・フランス市場
・イギリス市場
・イタリア市場
・ロシア市場

中東・アフリカ市場
・中東・アフリカの国別の脂質低下薬剤販売量、売上(2018-2023)
・中東・アフリカの脂質低下薬剤の種類別販売量
・中東・アフリカの脂質低下薬剤の用途別販売量
・エジプト市場
・南アフリカ市場
・イスラエル市場
・トルコ市場
・GCC諸国市場

市場の成長要因、課題、動向
・市場の成長要因および成長機会分析
・市場の課題およびリスク
・市場動向

製造コスト構造分析
・原材料とサプライヤー
・脂質低下薬剤の製造コスト構造分析
・脂質低下薬剤の製造プロセス分析
・脂質低下薬剤の産業チェーン構造

マーケティング、販売業者および顧客
・販売チャンネル:直接販売チャンネル、間接販売チャンネル
・脂質低下薬剤の主要なグローバル販売業者
・脂質低下薬剤の主要なグローバル顧客

地域別の脂質低下薬剤市場予測レビュー
・地域別の脂質低下薬剤市場規模予測(2024-2029)
・南北アメリカの国別予測
・アジア太平洋の国別予測
・ヨーロッパの国別予測
・脂質低下薬剤の種類別市場規模予測
・脂質低下薬剤の用途別市場規模予測

主要企業分析
Sanofi、 Pfizer, Inc.、 GlaxoSmithKline plc、 Novartis AG、 Merck & Co., Inc.、 Amgen Inc.、 Takeda Pharmaceutical Company Limited、 Sun Pharmaceutical Industries Ltd.、 AbbVie, Inc.、 Viatris (Mylan N.V.)、 AstraZeneca PLC、 Dr. Reddy’s Laboratories Ltd.
・企業情報
・脂質低下薬剤製品
・脂質低下薬剤販売量、売上、価格、粗利益(2018-2023)
・主要ビジネス概要
・最新動向

調査結果および結論

❖ レポートの目次 ❖

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Lipid-lowering Drugs Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Lipid-lowering Drugs by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Lipid-lowering Drugs by Country/Region, 2018, 2022 & 2029
2.2 Lipid-lowering Drugs Segment by Type
2.2.1 Statins & Combination
2.2.2 PCSK9 Inhibitors
2.2.3 Bile Acid Sequestrants
2.2.4 Fibrates
2.2.5 Cholesterol Absorption Inhibitors
2.2.6 Others
2.3 Lipid-lowering Drugs Sales by Type
2.3.1 Global Lipid-lowering Drugs Sales Market Share by Type (2018-2023)
2.3.2 Global Lipid-lowering Drugs Revenue and Market Share by Type (2018-2023)
2.3.3 Global Lipid-lowering Drugs Sale Price by Type (2018-2023)
2.4 Lipid-lowering Drugs Segment by Application
2.4.1 Hospital Pharmacies
2.4.2 Retail Pharmacies
2.4.3 Online Pharmacies
2.5 Lipid-lowering Drugs Sales by Application
2.5.1 Global Lipid-lowering Drugs Sale Market Share by Application (2018-2023)
2.5.2 Global Lipid-lowering Drugs Revenue and Market Share by Application (2018-2023)
2.5.3 Global Lipid-lowering Drugs Sale Price by Application (2018-2023)
3 Global Lipid-lowering Drugs by Company
3.1 Global Lipid-lowering Drugs Breakdown Data by Company
3.1.1 Global Lipid-lowering Drugs Annual Sales by Company (2018-2023)
3.1.2 Global Lipid-lowering Drugs Sales Market Share by Company (2018-2023)
3.2 Global Lipid-lowering Drugs Annual Revenue by Company (2018-2023)
3.2.1 Global Lipid-lowering Drugs Revenue by Company (2018-2023)
3.2.2 Global Lipid-lowering Drugs Revenue Market Share by Company (2018-2023)
3.3 Global Lipid-lowering Drugs Sale Price by Company
3.4 Key Manufacturers Lipid-lowering Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Lipid-lowering Drugs Product Location Distribution
3.4.2 Players Lipid-lowering Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Lipid-lowering Drugs by Geographic Region
4.1 World Historic Lipid-lowering Drugs Market Size by Geographic Region (2018-2023)
4.1.1 Global Lipid-lowering Drugs Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Lipid-lowering Drugs Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Lipid-lowering Drugs Market Size by Country/Region (2018-2023)
4.2.1 Global Lipid-lowering Drugs Annual Sales by Country/Region (2018-2023)
4.2.2 Global Lipid-lowering Drugs Annual Revenue by Country/Region (2018-2023)
4.3 Americas Lipid-lowering Drugs Sales Growth
4.4 APAC Lipid-lowering Drugs Sales Growth
4.5 Europe Lipid-lowering Drugs Sales Growth
4.6 Middle East & Africa Lipid-lowering Drugs Sales Growth
5 Americas
5.1 Americas Lipid-lowering Drugs Sales by Country
5.1.1 Americas Lipid-lowering Drugs Sales by Country (2018-2023)
5.1.2 Americas Lipid-lowering Drugs Revenue by Country (2018-2023)
5.2 Americas Lipid-lowering Drugs Sales by Type
5.3 Americas Lipid-lowering Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Lipid-lowering Drugs Sales by Region
6.1.1 APAC Lipid-lowering Drugs Sales by Region (2018-2023)
6.1.2 APAC Lipid-lowering Drugs Revenue by Region (2018-2023)
6.2 APAC Lipid-lowering Drugs Sales by Type
6.3 APAC Lipid-lowering Drugs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Lipid-lowering Drugs by Country
7.1.1 Europe Lipid-lowering Drugs Sales by Country (2018-2023)
7.1.2 Europe Lipid-lowering Drugs Revenue by Country (2018-2023)
7.2 Europe Lipid-lowering Drugs Sales by Type
7.3 Europe Lipid-lowering Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Lipid-lowering Drugs by Country
8.1.1 Middle East & Africa Lipid-lowering Drugs Sales by Country (2018-2023)
8.1.2 Middle East & Africa Lipid-lowering Drugs Revenue by Country (2018-2023)
8.2 Middle East & Africa Lipid-lowering Drugs Sales by Type
8.3 Middle East & Africa Lipid-lowering Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Lipid-lowering Drugs
10.3 Manufacturing Process Analysis of Lipid-lowering Drugs
10.4 Industry Chain Structure of Lipid-lowering Drugs
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Lipid-lowering Drugs Distributors
11.3 Lipid-lowering Drugs Customer
12 World Forecast Review for Lipid-lowering Drugs by Geographic Region
12.1 Global Lipid-lowering Drugs Market Size Forecast by Region
12.1.1 Global Lipid-lowering Drugs Forecast by Region (2024-2029)
12.1.2 Global Lipid-lowering Drugs Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Lipid-lowering Drugs Forecast by Type
12.7 Global Lipid-lowering Drugs Forecast by Application
13 Key Players Analysis
13.1 Sanofi
13.1.1 Sanofi Company Information
13.1.2 Sanofi Lipid-lowering Drugs Product Portfolios and Specifications
13.1.3 Sanofi Lipid-lowering Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Sanofi Main Business Overview
13.1.5 Sanofi Latest Developments
13.2 Pfizer, Inc.
13.2.1 Pfizer, Inc. Company Information
13.2.2 Pfizer, Inc. Lipid-lowering Drugs Product Portfolios and Specifications
13.2.3 Pfizer, Inc. Lipid-lowering Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Pfizer, Inc. Main Business Overview
13.2.5 Pfizer, Inc. Latest Developments
13.3 GlaxoSmithKline plc
13.3.1 GlaxoSmithKline plc Company Information
13.3.2 GlaxoSmithKline plc Lipid-lowering Drugs Product Portfolios and Specifications
13.3.3 GlaxoSmithKline plc Lipid-lowering Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 GlaxoSmithKline plc Main Business Overview
13.3.5 GlaxoSmithKline plc Latest Developments
13.4 Novartis AG
13.4.1 Novartis AG Company Information
13.4.2 Novartis AG Lipid-lowering Drugs Product Portfolios and Specifications
13.4.3 Novartis AG Lipid-lowering Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Novartis AG Main Business Overview
13.4.5 Novartis AG Latest Developments
13.5 Merck & Co., Inc.
13.5.1 Merck & Co., Inc. Company Information
13.5.2 Merck & Co., Inc. Lipid-lowering Drugs Product Portfolios and Specifications
13.5.3 Merck & Co., Inc. Lipid-lowering Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Merck & Co., Inc. Main Business Overview
13.5.5 Merck & Co., Inc. Latest Developments
13.6 Amgen Inc.
13.6.1 Amgen Inc. Company Information
13.6.2 Amgen Inc. Lipid-lowering Drugs Product Portfolios and Specifications
13.6.3 Amgen Inc. Lipid-lowering Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Amgen Inc. Main Business Overview
13.6.5 Amgen Inc. Latest Developments
13.7 Takeda Pharmaceutical Company Limited
13.7.1 Takeda Pharmaceutical Company Limited Company Information
13.7.2 Takeda Pharmaceutical Company Limited Lipid-lowering Drugs Product Portfolios and Specifications
13.7.3 Takeda Pharmaceutical Company Limited Lipid-lowering Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Takeda Pharmaceutical Company Limited Main Business Overview
13.7.5 Takeda Pharmaceutical Company Limited Latest Developments
13.8 Sun Pharmaceutical Industries Ltd.
13.8.1 Sun Pharmaceutical Industries Ltd. Company Information
13.8.2 Sun Pharmaceutical Industries Ltd. Lipid-lowering Drugs Product Portfolios and Specifications
13.8.3 Sun Pharmaceutical Industries Ltd. Lipid-lowering Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Sun Pharmaceutical Industries Ltd. Main Business Overview
13.8.5 Sun Pharmaceutical Industries Ltd. Latest Developments
13.9 AbbVie, Inc.
13.9.1 AbbVie, Inc. Company Information
13.9.2 AbbVie, Inc. Lipid-lowering Drugs Product Portfolios and Specifications
13.9.3 AbbVie, Inc. Lipid-lowering Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 AbbVie, Inc. Main Business Overview
13.9.5 AbbVie, Inc. Latest Developments
13.10 Viatris (Mylan N.V.)
13.10.1 Viatris (Mylan N.V.) Company Information
13.10.2 Viatris (Mylan N.V.) Lipid-lowering Drugs Product Portfolios and Specifications
13.10.3 Viatris (Mylan N.V.) Lipid-lowering Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Viatris (Mylan N.V.) Main Business Overview
13.10.5 Viatris (Mylan N.V.) Latest Developments
13.11 AstraZeneca PLC
13.11.1 AstraZeneca PLC Company Information
13.11.2 AstraZeneca PLC Lipid-lowering Drugs Product Portfolios and Specifications
13.11.3 AstraZeneca PLC Lipid-lowering Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 AstraZeneca PLC Main Business Overview
13.11.5 AstraZeneca PLC Latest Developments
13.12 Dr. Reddy’s Laboratories Ltd.
13.12.1 Dr. Reddy’s Laboratories Ltd. Company Information
13.12.2 Dr. Reddy’s Laboratories Ltd. Lipid-lowering Drugs Product Portfolios and Specifications
13.12.3 Dr. Reddy’s Laboratories Ltd. Lipid-lowering Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Dr. Reddy’s Laboratories Ltd. Main Business Overview
13.12.5 Dr. Reddy’s Laboratories Ltd. Latest Developments
14 Research Findings and Conclusion

List of Tables
Table 1. Lipid-lowering Drugs Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Lipid-lowering Drugs Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Statins & Combination
Table 4. Major Players of PCSK9 Inhibitors
Table 5. Major Players of Bile Acid Sequestrants
Table 6. Major Players of Fibrates
Table 7. Major Players of Cholesterol Absorption Inhibitors
Table 8. Major Players of Others
Table 9. Global Lipid-lowering Drugs Sales by Type (2018-2023) & (K Units)
Table 10. Global Lipid-lowering Drugs Sales Market Share by Type (2018-2023)
Table 11. Global Lipid-lowering Drugs Revenue by Type (2018-2023) & ($ million)
Table 12. Global Lipid-lowering Drugs Revenue Market Share by Type (2018-2023)
Table 13. Global Lipid-lowering Drugs Sale Price by Type (2018-2023) & (US$/Unit)
Table 14. Global Lipid-lowering Drugs Sales by Application (2018-2023) & (K Units)
Table 15. Global Lipid-lowering Drugs Sales Market Share by Application (2018-2023)
Table 16. Global Lipid-lowering Drugs Revenue by Application (2018-2023)
Table 17. Global Lipid-lowering Drugs Revenue Market Share by Application (2018-2023)
Table 18. Global Lipid-lowering Drugs Sale Price by Application (2018-2023) & (US$/Unit)
Table 19. Global Lipid-lowering Drugs Sales by Company (2018-2023) & (K Units)
Table 20. Global Lipid-lowering Drugs Sales Market Share by Company (2018-2023)
Table 21. Global Lipid-lowering Drugs Revenue by Company (2018-2023) ($ Millions)
Table 22. Global Lipid-lowering Drugs Revenue Market Share by Company (2018-2023)
Table 23. Global Lipid-lowering Drugs Sale Price by Company (2018-2023) & (US$/Unit)
Table 24. Key Manufacturers Lipid-lowering Drugs Producing Area Distribution and Sales Area
Table 25. Players Lipid-lowering Drugs Products Offered
Table 26. Lipid-lowering Drugs Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 27. New Products and Potential Entrants
Table 28. Mergers & Acquisitions, Expansion
Table 29. Global Lipid-lowering Drugs Sales by Geographic Region (2018-2023) & (K Units)
Table 30. Global Lipid-lowering Drugs Sales Market Share Geographic Region (2018-2023)
Table 31. Global Lipid-lowering Drugs Revenue by Geographic Region (2018-2023) & ($ millions)
Table 32. Global Lipid-lowering Drugs Revenue Market Share by Geographic Region (2018-2023)
Table 33. Global Lipid-lowering Drugs Sales by Country/Region (2018-2023) & (K Units)
Table 34. Global Lipid-lowering Drugs Sales Market Share by Country/Region (2018-2023)
Table 35. Global Lipid-lowering Drugs Revenue by Country/Region (2018-2023) & ($ millions)
Table 36. Global Lipid-lowering Drugs Revenue Market Share by Country/Region (2018-2023)
Table 37. Americas Lipid-lowering Drugs Sales by Country (2018-2023) & (K Units)
Table 38. Americas Lipid-lowering Drugs Sales Market Share by Country (2018-2023)
Table 39. Americas Lipid-lowering Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 40. Americas Lipid-lowering Drugs Revenue Market Share by Country (2018-2023)
Table 41. Americas Lipid-lowering Drugs Sales by Type (2018-2023) & (K Units)
Table 42. Americas Lipid-lowering Drugs Sales by Application (2018-2023) & (K Units)
Table 43. APAC Lipid-lowering Drugs Sales by Region (2018-2023) & (K Units)
Table 44. APAC Lipid-lowering Drugs Sales Market Share by Region (2018-2023)
Table 45. APAC Lipid-lowering Drugs Revenue by Region (2018-2023) & ($ Millions)
Table 46. APAC Lipid-lowering Drugs Revenue Market Share by Region (2018-2023)
Table 47. APAC Lipid-lowering Drugs Sales by Type (2018-2023) & (K Units)
Table 48. APAC Lipid-lowering Drugs Sales by Application (2018-2023) & (K Units)
Table 49. Europe Lipid-lowering Drugs Sales by Country (2018-2023) & (K Units)
Table 50. Europe Lipid-lowering Drugs Sales Market Share by Country (2018-2023)
Table 51. Europe Lipid-lowering Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 52. Europe Lipid-lowering Drugs Revenue Market Share by Country (2018-2023)
Table 53. Europe Lipid-lowering Drugs Sales by Type (2018-2023) & (K Units)
Table 54. Europe Lipid-lowering Drugs Sales by Application (2018-2023) & (K Units)
Table 55. Middle East & Africa Lipid-lowering Drugs Sales by Country (2018-2023) & (K Units)
Table 56. Middle East & Africa Lipid-lowering Drugs Sales Market Share by Country (2018-2023)
Table 57. Middle East & Africa Lipid-lowering Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 58. Middle East & Africa Lipid-lowering Drugs Revenue Market Share by Country (2018-2023)
Table 59. Middle East & Africa Lipid-lowering Drugs Sales by Type (2018-2023) & (K Units)
Table 60. Middle East & Africa Lipid-lowering Drugs Sales by Application (2018-2023) & (K Units)
Table 61. Key Market Drivers & Growth Opportunities of Lipid-lowering Drugs
Table 62. Key Market Challenges & Risks of Lipid-lowering Drugs
Table 63. Key Industry Trends of Lipid-lowering Drugs
Table 64. Lipid-lowering Drugs Raw Material
Table 65. Key Suppliers of Raw Materials
Table 66. Lipid-lowering Drugs Distributors List
Table 67. Lipid-lowering Drugs Customer List
Table 68. Global Lipid-lowering Drugs Sales Forecast by Region (2024-2029) & (K Units)
Table 69. Global Lipid-lowering Drugs Revenue Forecast by Region (2024-2029) & ($ millions)
Table 70. Americas Lipid-lowering Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 71. Americas Lipid-lowering Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 72. APAC Lipid-lowering Drugs Sales Forecast by Region (2024-2029) & (K Units)
Table 73. APAC Lipid-lowering Drugs Revenue Forecast by Region (2024-2029) & ($ millions)
Table 74. Europe Lipid-lowering Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 75. Europe Lipid-lowering Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 76. Middle East & Africa Lipid-lowering Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 77. Middle East & Africa Lipid-lowering Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 78. Global Lipid-lowering Drugs Sales Forecast by Type (2024-2029) & (K Units)
Table 79. Global Lipid-lowering Drugs Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 80. Global Lipid-lowering Drugs Sales Forecast by Application (2024-2029) & (K Units)
Table 81. Global Lipid-lowering Drugs Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 82. Sanofi Basic Information, Lipid-lowering Drugs Manufacturing Base, Sales Area and Its Competitors
Table 83. Sanofi Lipid-lowering Drugs Product Portfolios and Specifications
Table 84. Sanofi Lipid-lowering Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 85. Sanofi Main Business
Table 86. Sanofi Latest Developments
Table 87. Pfizer, Inc. Basic Information, Lipid-lowering Drugs Manufacturing Base, Sales Area and Its Competitors
Table 88. Pfizer, Inc. Lipid-lowering Drugs Product Portfolios and Specifications
Table 89. Pfizer, Inc. Lipid-lowering Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 90. Pfizer, Inc. Main Business
Table 91. Pfizer, Inc. Latest Developments
Table 92. GlaxoSmithKline plc Basic Information, Lipid-lowering Drugs Manufacturing Base, Sales Area and Its Competitors
Table 93. GlaxoSmithKline plc Lipid-lowering Drugs Product Portfolios and Specifications
Table 94. GlaxoSmithKline plc Lipid-lowering Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 95. GlaxoSmithKline plc Main Business
Table 96. GlaxoSmithKline plc Latest Developments
Table 97. Novartis AG Basic Information, Lipid-lowering Drugs Manufacturing Base, Sales Area and Its Competitors
Table 98. Novartis AG Lipid-lowering Drugs Product Portfolios and Specifications
Table 99. Novartis AG Lipid-lowering Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 100. Novartis AG Main Business
Table 101. Novartis AG Latest Developments
Table 102. Merck & Co., Inc. Basic Information, Lipid-lowering Drugs Manufacturing Base, Sales Area and Its Competitors
Table 103. Merck & Co., Inc. Lipid-lowering Drugs Product Portfolios and Specifications
Table 104. Merck & Co., Inc. Lipid-lowering Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 105. Merck & Co., Inc. Main Business
Table 106. Merck & Co., Inc. Latest Developments
Table 107. Amgen Inc. Basic Information, Lipid-lowering Drugs Manufacturing Base, Sales Area and Its Competitors
Table 108. Amgen Inc. Lipid-lowering Drugs Product Portfolios and Specifications
Table 109. Amgen Inc. Lipid-lowering Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 110. Amgen Inc. Main Business
Table 111. Amgen Inc. Latest Developments
Table 112. Takeda Pharmaceutical Company Limited Basic Information, Lipid-lowering Drugs Manufacturing Base, Sales Area and Its Competitors
Table 113. Takeda Pharmaceutical Company Limited Lipid-lowering Drugs Product Portfolios and Specifications
Table 114. Takeda Pharmaceutical Company Limited Lipid-lowering Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 115. Takeda Pharmaceutical Company Limited Main Business
Table 116. Takeda Pharmaceutical Company Limited Latest Developments
Table 117. Sun Pharmaceutical Industries Ltd. Basic Information, Lipid-lowering Drugs Manufacturing Base, Sales Area and Its Competitors
Table 118. Sun Pharmaceutical Industries Ltd. Lipid-lowering Drugs Product Portfolios and Specifications
Table 119. Sun Pharmaceutical Industries Ltd. Lipid-lowering Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 120. Sun Pharmaceutical Industries Ltd. Main Business
Table 121. Sun Pharmaceutical Industries Ltd. Latest Developments
Table 122. AbbVie, Inc. Basic Information, Lipid-lowering Drugs Manufacturing Base, Sales Area and Its Competitors
Table 123. AbbVie, Inc. Lipid-lowering Drugs Product Portfolios and Specifications
Table 124. AbbVie, Inc. Lipid-lowering Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 125. AbbVie, Inc. Main Business
Table 126. AbbVie, Inc. Latest Developments
Table 127. Viatris (Mylan N.V.) Basic Information, Lipid-lowering Drugs Manufacturing Base, Sales Area and Its Competitors
Table 128. Viatris (Mylan N.V.) Lipid-lowering Drugs Product Portfolios and Specifications
Table 129. Viatris (Mylan N.V.) Lipid-lowering Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 130. Viatris (Mylan N.V.) Main Business
Table 131. Viatris (Mylan N.V.) Latest Developments
Table 132. AstraZeneca PLC Basic Information, Lipid-lowering Drugs Manufacturing Base, Sales Area and Its Competitors
Table 133. AstraZeneca PLC Lipid-lowering Drugs Product Portfolios and Specifications
Table 134. AstraZeneca PLC Lipid-lowering Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 135. AstraZeneca PLC Main Business
Table 136. AstraZeneca PLC Latest Developments
Table 137. Dr. Reddy’s Laboratories Ltd. Basic Information, Lipid-lowering Drugs Manufacturing Base, Sales Area and Its Competitors
Table 138. Dr. Reddy’s Laboratories Ltd. Lipid-lowering Drugs Product Portfolios and Specifications
Table 139. Dr. Reddy’s Laboratories Ltd. Lipid-lowering Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 140. Dr. Reddy’s Laboratories Ltd. Main Business
Table 141. Dr. Reddy’s Laboratories Ltd. Latest Developments
List of Figures
Figure 1. Picture of Lipid-lowering Drugs
Figure 2. Lipid-lowering Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Lipid-lowering Drugs Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Lipid-lowering Drugs Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Lipid-lowering Drugs Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Statins & Combination
Figure 10. Product Picture of PCSK9 Inhibitors
Figure 11. Product Picture of Bile Acid Sequestrants
Figure 12. Product Picture of Fibrates
Figure 13. Product Picture of Cholesterol Absorption Inhibitors
Figure 14. Product Picture of Others
Figure 15. Global Lipid-lowering Drugs Sales Market Share by Type in 2022
Figure 16. Global Lipid-lowering Drugs Revenue Market Share by Type (2018-2023)
Figure 17. Lipid-lowering Drugs Consumed in Hospital Pharmacies
Figure 18. Global Lipid-lowering Drugs Market: Hospital Pharmacies (2018-2023) & (K Units)
Figure 19. Lipid-lowering Drugs Consumed in Retail Pharmacies
Figure 20. Global Lipid-lowering Drugs Market: Retail Pharmacies (2018-2023) & (K Units)
Figure 21. Lipid-lowering Drugs Consumed in Online Pharmacies
Figure 22. Global Lipid-lowering Drugs Market: Online Pharmacies (2018-2023) & (K Units)
Figure 23. Global Lipid-lowering Drugs Sales Market Share by Application (2022)
Figure 24. Global Lipid-lowering Drugs Revenue Market Share by Application in 2022
Figure 25. Lipid-lowering Drugs Sales Market by Company in 2022 (K Units)
Figure 26. Global Lipid-lowering Drugs Sales Market Share by Company in 2022
Figure 27. Lipid-lowering Drugs Revenue Market by Company in 2022 ($ Million)
Figure 28. Global Lipid-lowering Drugs Revenue Market Share by Company in 2022
Figure 29. Global Lipid-lowering Drugs Sales Market Share by Geographic Region (2018-2023)
Figure 30. Global Lipid-lowering Drugs Revenue Market Share by Geographic Region in 2022
Figure 31. Americas Lipid-lowering Drugs Sales 2018-2023 (K Units)
Figure 32. Americas Lipid-lowering Drugs Revenue 2018-2023 ($ Millions)
Figure 33. APAC Lipid-lowering Drugs Sales 2018-2023 (K Units)
Figure 34. APAC Lipid-lowering Drugs Revenue 2018-2023 ($ Millions)
Figure 35. Europe Lipid-lowering Drugs Sales 2018-2023 (K Units)
Figure 36. Europe Lipid-lowering Drugs Revenue 2018-2023 ($ Millions)
Figure 37. Middle East & Africa Lipid-lowering Drugs Sales 2018-2023 (K Units)
Figure 38. Middle East & Africa Lipid-lowering Drugs Revenue 2018-2023 ($ Millions)
Figure 39. Americas Lipid-lowering Drugs Sales Market Share by Country in 2022
Figure 40. Americas Lipid-lowering Drugs Revenue Market Share by Country in 2022
Figure 41. Americas Lipid-lowering Drugs Sales Market Share by Type (2018-2023)
Figure 42. Americas Lipid-lowering Drugs Sales Market Share by Application (2018-2023)
Figure 43. United States Lipid-lowering Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 44. Canada Lipid-lowering Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 45. Mexico Lipid-lowering Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 46. Brazil Lipid-lowering Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 47. APAC Lipid-lowering Drugs Sales Market Share by Region in 2022
Figure 48. APAC Lipid-lowering Drugs Revenue Market Share by Regions in 2022
Figure 49. APAC Lipid-lowering Drugs Sales Market Share by Type (2018-2023)
Figure 50. APAC Lipid-lowering Drugs Sales Market Share by Application (2018-2023)
Figure 51. China Lipid-lowering Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 52. Japan Lipid-lowering Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 53. South Korea Lipid-lowering Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 54. Southeast Asia Lipid-lowering Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 55. India Lipid-lowering Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 56. Australia Lipid-lowering Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 57. China Taiwan Lipid-lowering Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 58. Europe Lipid-lowering Drugs Sales Market Share by Country in 2022
Figure 59. Europe Lipid-lowering Drugs Revenue Market Share by Country in 2022
Figure 60. Europe Lipid-lowering Drugs Sales Market Share by Type (2018-2023)
Figure 61. Europe Lipid-lowering Drugs Sales Market Share by Application (2018-2023)
Figure 62. Germany Lipid-lowering Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 63. France Lipid-lowering Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 64. UK Lipid-lowering Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 65. Italy Lipid-lowering Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 66. Russia Lipid-lowering Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 67. Middle East & Africa Lipid-lowering Drugs Sales Market Share by Country in 2022
Figure 68. Middle East & Africa Lipid-lowering Drugs Revenue Market Share by Country in 2022
Figure 69. Middle East & Africa Lipid-lowering Drugs Sales Market Share by Type (2018-2023)
Figure 70. Middle East & Africa Lipid-lowering Drugs Sales Market Share by Application (2018-2023)
Figure 71. Egypt Lipid-lowering Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 72. South Africa Lipid-lowering Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 73. Israel Lipid-lowering Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 74. Turkey Lipid-lowering Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 75. GCC Country Lipid-lowering Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 76. Manufacturing Cost Structure Analysis of Lipid-lowering Drugs in 2022
Figure 77. Manufacturing Process Analysis of Lipid-lowering Drugs
Figure 78. Industry Chain Structure of Lipid-lowering Drugs
Figure 79. Channels of Distribution
Figure 80. Global Lipid-lowering Drugs Sales Market Forecast by Region (2024-2029)
Figure 81. Global Lipid-lowering Drugs Revenue Market Share Forecast by Region (2024-2029)
Figure 82. Global Lipid-lowering Drugs Sales Market Share Forecast by Type (2024-2029)
Figure 83. Global Lipid-lowering Drugs Revenue Market Share Forecast by Type (2024-2029)
Figure 84. Global Lipid-lowering Drugs Sales Market Share Forecast by Application (2024-2029)
Figure 85. Global Lipid-lowering Drugs Revenue Market Share Forecast by Application (2024-2029)


❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 脂質低下薬剤のグローバル市場予測2023-2029(Global Lipid-lowering Drugs Market Growth 2023-2029)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆